Compare Adaptive Biotechnologies Corp (ADPT) vs Arqit Quantum Inc (ARQQ) Price & Performance

ADPT trades at $24.46, down 3.66% today but remains near its 52-week high. The stock shows bullish technical signals with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025, while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to a pure-play MRD diagnostics business following the Immune Medicine separation has generated positive investor sentiment, with 65% of analysts maintaining buy ratings.

Outlook remains cautiously optimistic as ADPT's MRD business demonstrates strong growth potential with 49% YoY revenue expansion. Key risks include persistent negative profitability metrics and execution challenges during the business separation. The consensus price target of $25.50 suggests modest upside potential from current levels, contingent on continued operational improvement.

ARQQ trades at $23.72, down 2.75% today, with a bullish technical signal driven by moving averages. The stock shows extreme valuation metrics with a P/S of 343.93 and P/B of 14.52, while fundamentals reveal deep losses: revenue of $530K in 2025 against a net income margin of -4,508.1%. Recent news highlights progress in quantum-safe encryption partnerships, including a proof-of-concept with nLighten announced July 14, 2026.

Outlook remains speculative due to persistent losses and high cash burn, but growth catalysts include contract wins in telecom and government sectors. Key risks involve unsustainable margins and reliance on financing. Analyst sentiment is split evenly between Buy and Hold ratings, reflecting cautious optimism amid financial challenges.